As of 2025-07-05, the EV/EBITDA ratio of Kymera Therapeutics Inc (KYMR) is -10.47. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. KYMR's latest enterprise value is 2,830.23 mil USD. KYMR's TTM EBITDA according to its financial statements is -270.27 mil USD. Dividing these 2 quantities gives us the above KYMR EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 10.0x - 13.3x | 12.8x |
| Forward P/E multiples | 15.4x - 26.5x | 20.6x |
| Fair Price | (62.50) - (53.79) | (67.98) |
| Upside | -239.5% - -220.1% | -251.8% |
| Date | EV/EBITDA |
| 2025-07-03 | -10.47 |
| 2025-07-02 | -10.41 |
| 2025-07-01 | -10.39 |
| 2025-06-30 | -10.19 |
| 2025-06-27 | -10.31 |
| 2025-06-26 | -10.69 |
| 2025-06-25 | -10.88 |
| 2025-06-24 | -11.04 |
| 2025-06-23 | -10.83 |
| 2025-06-20 | -10.73 |
| 2025-06-18 | -10.87 |
| 2025-06-17 | -10.85 |
| 2025-06-16 | -10.97 |
| 2025-06-13 | -10.99 |
| 2025-06-12 | -11.07 |
| 2025-06-11 | -11.34 |
| 2025-06-10 | -11.39 |
| 2025-06-09 | -11.04 |
| 2025-06-06 | -11.15 |
| 2025-06-05 | -11.16 |
| 2025-06-04 | -10.34 |
| 2025-06-03 | -10.18 |
| 2025-06-02 | -10.07 |
| 2025-05-30 | -6.82 |
| 2025-05-29 | -6.97 |
| 2025-05-28 | -6.62 |
| 2025-05-27 | -6.46 |
| 2025-05-23 | -6.79 |
| 2025-05-22 | -6.95 |
| 2025-05-21 | -6.94 |
| 2025-05-20 | -7.26 |
| 2025-05-19 | -6.96 |
| 2025-05-16 | -6.97 |
| 2025-05-15 | -6.91 |
| 2025-05-14 | -6.85 |
| 2025-05-13 | -7.18 |
| 2025-05-12 | -7.43 |
| 2025-05-09 | -6.93 |
| 2025-05-08 | -7.09 |
| 2025-05-07 | -6.69 |
| 2025-05-06 | -6.56 |
| 2025-05-05 | -7.77 |
| 2025-05-02 | -8.18 |
| 2025-05-01 | -8.00 |
| 2025-04-30 | -7.94 |
| 2025-04-29 | -7.80 |
| 2025-04-28 | -7.78 |
| 2025-04-25 | -7.69 |
| 2025-04-24 | -7.77 |
| 2025-04-23 | -7.08 |